In 2014 study by Enokida et al. [14] on the rs309 MDM2 gene polymorphism in lung cancer, the distribution of genotypes showed no significant difference between lung cancer patients and controls (patients: TT, 20.1%; TG, 49.7%; and GG, 30.2%; controls: TT, 21.7%; TG, 47.9%; and GG, 30.4%). Here, MDM2 is linked to lung carcinoma.